Related Experiment Video
Updated: Jun 8, 2025
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.2K
Productivity Loss Associated with Disability from Migraine: A Canada-Wide Cross-Sectional Study
Hiten Naik1,2, Alexander C T Tam3, Logan Trenaman4
1Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Summary
Migraine significantly impacts productivity in employed adults, increasing both paid and unpaid work loss. Greater disability correlates with higher productivity losses, highlighting the economic burden of this condition.
Area of Science:
- Neurology
- Health Economics
- Occupational Health
Background:
- Migraine affects adults during their prime working years.
- Limited Canadian research exists on migraine-related disability and productivity loss.
- The impact of migraine on unpaid productivity loss remains unquantified.
Purpose of the Study:
- To quantify the association between migraine-related disability and productivity loss in employed Canadian adults.
- To assess both paid and unpaid productivity losses.
- To provide data for evaluating the cost-effectiveness of migraine treatments.
Main Methods:
- Cross-sectional study of employed adults with migraine across Canada.
- Web-based questionnaire assessing migraine disability (MIDAS) and productivity loss (VOLP).
- Multiple regression models adjusted for clinical, occupational, and sociodemographic factors.
Main Results:
- 441 participants (60.1% female, mean age 37.7).
- Higher disability levels correlated with increased total productivity loss (moderate: 54.1 hrs; severe: 110.5 hrs per 3 months).
- Paid productivity loss increased with disability (moderate: 32.4 hrs; severe: 61.6 hrs per 3 months), and unpaid loss was greater in severe disability (43.5 hrs per 3 months).
Conclusions:
- Increased migraine-related disability is linked to greater total, paid, and unpaid productivity loss.
- Findings underscore the significant economic impact of migraine on the workforce.
- Data are crucial for assessing the cost-effectiveness of new migraine therapies.
